In conclusion, our study demonstrated that RPL22L1 is a key promoter of PCa and promotes PCa cell proliferation and invasion through PI3K/Akt/mTOR pathway, thus potentially providing a new target for PCa therapy. The gene discussed is MTOR; the disease is posterior cortical atrophy.